Paper typeRandomised Controlled Trial
ReferenceBernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF et al.
Efficacy and safety of recombinant human activated protein C for severe sepsis.
New England Journal of Medicine 2001; 344: 699-709.
Major FindingFor every 16 patients with sepsis given activated protein C, compared to placebo, one less patient dies. The risk of bleeding complications may be increased.
Point for discussion:As a result of the extensive correspondance relating to this and the subsequent APC trials are ICU clinicians as keen to prescribe APPC as they were when this study was first reported?